We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Increased Levels of Serum Amyloid-beta Linked to Development of Cardiovascular Disease

By LabMedica International staff writers
Posted on 04 Mar 2020
A new review article has summarized studies, which suggest that the Alzheimer’s disease (AD) biomarker amyloid-beta (Abeta) has a causitive link to other age-related conditions such as cardiovascular disease (CVD).

Investigators at Newcastle University (United Kingdom) in collaboration with colleagues in Greece, Germany, Switzerland, and the United States analyzed blood samples from more than 6,600 patients from multiple cohort studies carried out in nine countries.

In the review, which was published in the February 24, 2020, online edition of the Journal of the American College of Cardiology, the investigators described the determinants of Abeta metabolism, summarized the effects of Abeta on atherothrombosis and cardiac dysfunction, discussed the clinical value of Αbeta1-40 in CVD prognosis and patient risk stratification, and presented therapeutic interventions that may alter Abeta metabolism in humans.

Overall, the findings discussed in the review suggested that the higher the level of amyloid-beta in the blood the higher the risk of developing CVD.

Senior author Dr. More...
Konstantinos Stellos, professor of cardiovascular medicine and epitranscriptomics at Newcastle University, said, "Our work has created and put all the pieces of the puzzle together. For the first time, we have provided evidence of the involvement of amyloid-beta in early and later stages of cardiovascular disease. What is really exciting is that we were able to reproduce these unexpected, clinically meaningful findings in patients from around the world. In all cases, we observed that amyloid-beta is a biomarker of cardiovascular ageing and of cardiovascular disease prognosis."

"I am interested in knowing which of my patients is at risk of death and/or recurrent heart attacks," said Professor Stellos. "Measuring amyloid-beta reclassified a large proportion of patients who had a heart attack in the correct risk categories over an established guideline-suggested risk score in independent clinical studies. If blood-based amyloid-beta predicts death in patients with heart disease, does it make a therapeutic target? Our next step is to investigate this."

Related Links:
Newcastle University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.